Viking Therapeutics (STU:1VT) Retained Earnings: €-870.08 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1VT Viking Therapeutics Inc STU:1VT
38 GF Score
Price €29.00
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics Retained Earnings?

Viking Therapeutics STU:1VT -2.36% 38 Retained Earnings is €-870.08 Mil as of Mar. 2026. GuruFocus rates STU:1VT with a GF Score™ of 38/100. The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Viking Therapeutics's retained earnings for the quarter that ended in Mar. 2026 was €-870.08 Mil.

Viking Therapeutics's quarterly retained earnings declined from Sep. 2025 (€-587.78 Mil) to Dec. 2025 (€-723.80 Mil) and declined from Dec. 2025 (€-723.80 Mil) to Mar. 2026 (€-870.08 Mil).

Viking Therapeutics's annual retained earnings declined from Dec. 2023 (€-346.58 Mil) to Dec. 2024 (€-465.95 Mil) and declined from Dec. 2024 (€-465.95 Mil) to Dec. 2025 (€-723.80 Mil).


Viking Therapeutics  (STU:1VT) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Viking Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Viking Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viking Therapeutics Retained Earnings Chart

Viking Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -197.52 -275.69 -346.58 -465.95 -723.80

Viking Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -493.52 -519.42 -587.78 -723.80 -870.08
STU:1VT
38GF Score
Viking Therapeutics Inc STU:1VT
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viking Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-870.08 Mil mean?
Viking Therapeutics (STU:1VT) has a Retained Earnings of €-870.08 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Viking Therapeutics and its competitors.
Is Viking Therapeutics' Retained Earnings too high?
Viking Therapeutics' current Retained Earnings is €-870.08 Mil. Overall, Viking Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' Retained Earnings compare to DYN and CELC?
Viking Therapeutics' Retained Earnings of €-870.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Viking Therapeutics and its competitors. Viking Therapeutics's current Retained Earnings is €-870.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (STU:1VT) has a current Retained Earnings of €-870.08 Mil. The current Retained Earnings is €-870.08 Mil. Viking Therapeutics' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Viking Therapeutics (STU:1VT), the current Retained Earnings is €-870.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viking Therapeutics Business Description

Other Exchanges VKTX:USA1VKTX:Italy0VQA:UK
Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
38GF Score

Get the complete analysis for STU:1VT

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.00
Price